Shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus target price of $7.00 for the company, according to Zacks. Zacks has also assigned Matinas BioPharma Holdings an industry rank of 107 out of 265 based on the ratings given to its competitors.
Several research firms have recently issued reports on MTNB. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Matinas BioPharma Holdings in a research note on Monday, April 3rd. Aegis reaffirmed a “positive” rating and issued a $8.00 price objective on shares of Matinas BioPharma Holdings in a research note on Tuesday, March 28th.
A hedge fund recently bought a new stake in Matinas BioPharma Holdings stock. Raymond James Financial Services Advisors Inc. bought a new position in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 643,066 shares of the company’s stock, valued at approximately $1,781,000. Raymond James Financial Services Advisors Inc. owned about 0.72% of Matinas BioPharma Holdings at the end of the most recent reporting period.
Shares of Matinas BioPharma Holdings (NASDAQ:MTNB) traded down 5.15% on Thursday, hitting $2.58. 115,519 shares of the stock traded hands. Matinas BioPharma Holdings has a 1-year low of $0.45 and a 1-year high of $3.99. The stock’s market cap is $229.76 million. The stock has a 50 day moving average of $2.86 and a 200-day moving average of $2.31.
Matinas BioPharma Holdings (NASDAQ:MTNB) last released its quarterly earnings data on Monday, April 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.05. On average, equities research analysts expect that Matinas BioPharma Holdings will post ($0.16) EPS for the current year.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.